Clinical Treatment Decisions for Advanced Renal Cell Cancer

被引：14

作者：

Choueiri, Toni K. ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Kidney Canc Ctr, Boston, MA 02115 USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2013年 / 11卷 / 5.5期

关键词：

PROGNOSTIC MODEL; CARCINOMA; SURVIVAL; AXITINIB;

D O I：

10.6004/jnccn.2013.0204

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Seven targeted agents have improved the prognosis of advanced renal cell carcinoma (RCC), but none are effective in the post-nephrectomy adjuvant setting. Among the available first-line options for advanced RCC, sunitinib remains the most commonly used first-line therapy, but several studies suggest pazopanib may be better tolerated. Increasingly, choice of therapy may be driven by toxicity profiles. Cytoreductive nephrectomy remains important, even in the era of targeted therapies in selected patients.

引用

页码：694 / 697

页数：4

共 14 条

[1]

Al-Marrawi MY, TARGET ONCO IN PRESS

[2]

Bono P, 2012, J CLIN ONCOL S15, V30

[3]

The Impact of Cytoreductive Nephrectomy on Survival of Patients With Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Targeted Therapy [J].

Choueiri, Toni K. ;

Xie, Wanling ;

Kollmannsberger, Christian ;

North, Scott ;

Knox, Jennifer J. ;

Lampard, J. Geoffrey ;

McDermott, David F. ;

Rini, Brian I. ;

Heng, Daniel Y. C. .

JOURNAL OF UROLOGY, 2011, 185 (01) :60-66

[4]

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study [J].

Heng, Daniel Y. C. ;

Xie, Wanling ;

Regan, Meredith M. ;

Harshman, Lauren C. ;

Bjarnason, Georg A. ;

Vaishampayan, Ulka N. ;

Mackenzie, Mary ;

Wood, Lori ;

Donskov, Frede ;

Tan, Min-Han ;

Rha, Sun-Young ;

Agarwal, Neeraj ;

Kollmannsberger, Christian ;

Rini, Brian I. ;

Choueiri, Toni K. .

LANCET ONCOLOGY, 2013, 14 (02) :141-148

[5]

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study [J].

Heng, Daniel Y. C. ;

Xie, Wanling ;

Regan, Meredith M. ;

Warren, Mark A. ;

Golshayan, Ali Reza ;

Sahi, Chakshu ;

Eigl, Bernhard J. ;

Ruether, J. Dean ;

Cheng, Tina ;

North, Scott ;

Venner, Peter ;

Knox, Jennifer J. ;

Chi, Kim N. ;

Kollmannsberger, Christian ;

McDermott, David F. ;

Oh, William K. ;

Atkins, Michael B. ;

Bukowski, Ronald M. ;

Rini, Brian I. ;

Choueiri, Toni K. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) :5794-5799

[6]

Hutson T, 2012, 37 ANN ESMO C SEPT 2

[7]

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC) [J].

Hutson, Thomas E. ;

Gallardo, Jorge ;

Lesovoy, Vladmir ;

Al-Shukri, Salman ;

Stus, Viktor ;

Bair, A. H. ;

Rosbrook, Brad ;

Bycott, Paul W. ;

Tarazi, Jamal Christo ;

Kim, Sinil ;

Vogelzang, Nicholas J. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)

[8]

Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group [J].

Manola, Judith ;

Royston, Patrick ;

Elson, Paul ;

McCormack, Jennifer Bacik ;

Mazumdar, Madhu ;

Negrier, Sylvie ;

Escudier, Bernard ;

Eisen, Tim ;

Dutcher, Janice ;

Atkins, Michael ;

Heng, Daniel Y. C. ;

Choueiri, Toni K. ;

Motzer, Robert ;

Bukowski, Ronald .

CLINICAL CANCER RESEARCH, 2011, 17 (16) :5443-5450

[9]

Expression of topoisomerase (topo) II in adult acute myeloid leukemia (AML): Relationships to immunophenotype and treatment outcomes [J].

Michelson, A. P. ;

Kopecky, K. J. ;

Koegle, E. R. ;

Anderson, J. E. ;

Godwin, J. E. ;

Petersdorf, S. H. ;

List, A. F. ;

Willman, C. L. ;

Appelbaum, F. R. ;

Radich, J. P. ;

Ganapathi, M. K. ;

Ganapathi, R. N. ;

Advani, A. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[10]

Motzer RJ, 2012, J CLIN ONCOL S15, V30

← 1 2 →